Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia

  • Chaudhary, Ajay K (Department of Haematogenetics, National Institute of Immunohematology (NIIH-ICMR), King Edward Memorial Hospital Campus) ;
  • Chaudhary, Shruti (Department of Hematopathology, Tata Memorial Hospital) ;
  • Ghosh, Kanjaksha (Department of Haematogenetics, National Institute of Immunohematology (NIIH-ICMR), King Edward Memorial Hospital Campus) ;
  • Shanmukaiah, Chandrakala (Department of Hematology, King Edward Memorial Hospital) ;
  • Nadkarni, Anita H (Department of Haematogenetics, National Institute of Immunohematology (NIIH-ICMR), King Edward Memorial Hospital Campus)
  • Published : 2016.04.11
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Matrix metalloproteinase -2 (gelatinase-A, Mr 72,000 type IV collagenase, MMP-2) and -9 (gelatinase-B, Mr 92,000 type IV collagenase, MMP-9) are key molecules that play roles in tumor growth, invasion, tissue remodeling, metastasis and stem-cell regulation by digesting extracellular matrix barriers. MMP-2 and -9 are well known to impact on solid cancer susceptibility, whereas, in hematological malignancies, a paucity of data is available to resolve the function of these regulatory molecules in bone marrow mononuclear cells (BM-MNCs) and stromal cells of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Objectives: The present study aimed to investigate mRNA expression and gelatinase A and B secretion from BM-MNCs in vitro and genotypic associations of MMP-2 (-1306 C/T; rs243865), MMP-9 (-1562 C/T; rs3918242), tissue inhibitor of metalloproteinase -1 (TIMP-1) (372T/C; rs4898, Exon 5) and TIMP-2 (-418G/C; rs8179090) in MDS and AML. Results: The study covered cases of confirmed MDS (n=50), AML (n=32) and healthy controls (n=110). MMP-9 mRNA expression revealed 2 fold increased expression in MDS-RAEB II and 2.5 fold in AML M-4 (60-70% blasts). Secretion of gelatinase-B also revealed the MMP-9 mRNA expression and ELISA data also supported these data. We noted that those patients having more blast crises presented with more secretion of MMP-9 and its mRNA expression. In contrast MMP-9 (-1562 C/T) showed significant polymorphic associations in MDS (p<0.02) and AML (p<0.02). MMP-9 mRNA expression of C/T and T/T genotypes were 1.5 and 2.5 fold increased in MDS and AML respectively. In AML, MMP-2 C/T and T/T genotypes showed 2.0 fold mRNA expression. Only MMP-9 (-1306 C/T) showed significant 4 fold (p<0.001) increased risk with chemical and x-ray exposed MDS, while tobacco and cigarette smokers have 3 fold (p<0.04) risk in AML. Conclusions: In view of our results, MMP-9 revealed synergistic secretion and expression in blast crises of MDS and AML with 'gene' polymorphic effects and is significantly associated with increased risk with tobacco, cigarette and environmental exposure. Release and secretion of these enzymes may influence hematopoietic cell behavior and may be important in the clinical point of view. It may offer valuable tools for diagnosis and prognosis, as well as possible targets for the treatments.

Keywords

References

  1. Barille S, Akhoundi C, Collette M, et al (1997). Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood, 90, 1649-55.
  2. Chang YC, Yang SF, Tai KW, et al (2002). Increased tissue inhibitor of metalloproteinase-1 expression and inhibition of gelatinase A activity in buccal mucosal fibroblasts by arecoline as possible mechanisms for oral submucous fibrosis. Oral Oncol, 38, 195-200. https://doi.org/10.1016/S1368-8375(01)00045-8
  3. Chaubey R, Sazawal S, Dada R, et al (2011). Cytogenetic profile of Indian patients with de novo myelodysplastic syndromes. Indian J Med Res, 134, 452-7.
  4. Chaudhary AK, Pandya S, Ghosh K, et al (2013). Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: an overview. Mutat Res, 753, 7-23. https://doi.org/10.1016/j.mrrev.2013.01.002
  5. Chaudhary AK, Pandya S, Mehrotra R, et al (2010a). Functional polymorphism of the MMP-1 promoter (-1607 1G/2G) in potentially malignant and malignant head and neck lesions in an Indian population. Biomarkers, 15, 684-92. https://doi.org/10.3109/1354750X.2010.511267
  6. Chaudhary AK, Pandya S, Mehrotra R, et al (2011). Role of functional polymorphism of matrix metalloproteinase-2 (-1306 C/T and -168 G/T) and MMP-9 (-1562 C/T) promoter in oral submucous fibrosis and head and neck squamous cell carcinoma in an Indian population. Biomarkers, 16, 577-86. https://doi.org/10.3109/1354750X.2011.609602
  7. Chaudhary AK, Singh M, Bharti AC, et al (2010b). Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck. J Biomed Sci, 17, 10. https://doi.org/10.1186/1423-0127-17-10
  8. Dakshinamurthy AG, Novitzky N, Bharadwaj R, et al (2005). Cytogenetic analysis of 52 Indian patients with de novo myelodysplastic syndromes-a comparative analysis of results with reports from Asia. Ann Hematol, 84, 298-303. https://doi.org/10.1007/s00277-004-0997-x
  9. de Souza Fernandez T, Ornellas MH, Otero de Carvalho L, et al (2000). Chromosomal alterations associated with evolution from myelodysplastic syndrome to acute myeloid leukemia. Leuk Res, 24, 839-48. https://doi.org/10.1016/S0145-2126(00)00056-4
  10. Diao LP, Ma H, Wei GC, et al (2012). Matrix metalloproteinase-2 promoter and tissue inhibitor of metalloproteinase-2 gene polymorphisms in non-Hodgkin's lymphoma. Int J Cancer, 131, 1095-103. https://doi.org/10.1002/ijc.26483
  11. Egeblad M, Werb Z (2002). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer, 2, 161-74. https://doi.org/10.1038/nrc745
  12. Galm O, Suzuki H, Akiyama Y, et al (2005). Inactivation of the tissue inhibitor of metalloproteinases-2 gene by promoter hypermethylation in lymphoid malignancies. Oncogene, 24, 4799-805. https://doi.org/10.1038/sj.onc.1208599
  13. Gao H, Peng C, Liang B, et al (2014). beta6 integrin induces the expression of metalloproteinase-3 and metalloproteinase-9 in colon cancer cells via ERK-ETS1 pathway. Cancer Lett, 354, 427-37. https://doi.org/10.1016/j.canlet.2014.08.017
  14. Gouda HM, Khorshied MM, El Sissy MH, et al (2014). Association between matrix metalloproteinase 2 (MMP2) promoter polymorphisms and the susceptibility to non-Hodgkin's lymphoma in Egyptians. Ann Hematol, 93, 1313-8.
  15. Heissig B, Hattori K, Dias S, et al (2002). Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell, 109, 625-37. https://doi.org/10.1016/S0092-8674(02)00754-7
  16. Hwang TL, Changchien TT, Wang CC, et al (2014). Claudin-4 expression in gastric cancer cells enhances the invasion and is associated with the increased level of matrix metalloproteinase-2 and -9 expression. Oncol Lett, 8, 1367-71. https://doi.org/10.3892/ol.2014.2295
  17. Ishihara M, Nishida C, Tashiro Y, et al (2012). Plasmin inhibitor reduces T-cell lymphoid tumor growth by suppressing matrix metalloproteinase-9-dependent CD11b(+)/F4/80(+) myeloid cell recruitment. Leukemia, 26, 332-9. https://doi.org/10.1038/leu.2011.203
  18. Issa A, Le TX, Shoushtari AN, et al (2009). Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype. Cancer Res, 69, 349-57. https://doi.org/10.1158/0008-5472.CAN-08-1875
  19. Issa JP (2013). The myelodysplastic syndrome as a prototypical epigenetic disease. Blood, 121, 3811-7. https://doi.org/10.1182/blood-2013-02-451757
  20. Janowska-Wieczorek A, Majka M, Marquez-Curtis L, et al (2002). Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants. Leukemia, 16, 1160-6. https://doi.org/10.1038/sj.leu.2402486
  21. Kalluri R (2003). Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer, 3, 422-33. https://doi.org/10.1038/nrc1094
  22. Klepin HD, Rao AV, Pardee TS (2014). Acute myeloid leukemia and myelodysplastic syndromes in older adults. J Clin Oncol.
  23. Kossakowska AE, Edwards DR, Prusinkiewicz C, et al (1999). Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas. Blood, 94, 2080-9.
  24. Langers AM, Verspaget HW, Hawinkels LJ, et al (2012). MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients. Br J Cancer, 106, 1495-8. https://doi.org/10.1038/bjc.2012.80
  25. Lin LI, Lin DT, Chang CJ, et al (2002). Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia. Br J Haematol, 117, 835-41. https://doi.org/10.1046/j.1365-2141.2002.03510.x
  26. Lin SC, Chung MY, Huang JW, et al (2004). Correlation between functional genotypes in the matrix metalloproteinases-1 promoter and risk of oral squamous cell carcinomas. J Oral Pathol Med, 33, 323-6. https://doi.org/10.1111/j.1600-0714.2004.00214.x
  27. Marquez-Curtis LA, Dobrowsky A, Montano J, et al (2001). Matrix metalloproteinase and tissue inhibitors of metalloproteinase secretion by haematopoietic and stromal precursors and their production in normal and leukaemic long-term marrow cultures. Br J Haematol, 115, 595-604. https://doi.org/10.1046/j.1365-2141.2001.03160.x
  28. Ogawa M, Kawamoto M, Yamanaka N (2000). Matrix metalloproteinase and tissue inhibitor of metalloproteinase in human bone marrow tissues-an immunohistochemical study. J Nippon Med Sch, 67, 235-41. https://doi.org/10.1272/jnms.67.235
  29. Redondo-Munoz J, Ugarte-Berzal E, Terol MJ, et al (2010). Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain. Cancer Cell, 17, 160-72. https://doi.org/10.1016/j.ccr.2009.12.044
  30. Ries C, Loher F, Zang C, et al (1999). Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Clin Cancer Res, 5, 1115-24.
  31. Rollison DE, Howlader N, Smith MT, et al (2008). Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood, 112, 45-52. https://doi.org/10.1182/blood-2008-01-134858
  32. Roy R, Zurakowski D, Wischhusen J, et al (2014). Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies. Br J Cancer, 111, 1772-9. https://doi.org/10.1038/bjc.2014.462
  33. S VANN, Skarstedt M, Lofgren S, et al (2013). Gene polymorphism of matrix metalloproteinase-12 and -13 and association with colorectal cancer in Swedish patients. Anticancer Res, 33, 3247-50.
  34. Sawyers CL, Denny CT, Witte ON (1991). Leukemia and the disruption of normal hematopoiesis. Cell, 64, 337-50. https://doi.org/10.1016/0092-8674(91)90643-D
  35. Schnerch D, Yalcintepe J, Schmidts A, et al (2012). Cell cycle control in acute myeloid leukemia. Am J Cancer Res, 2, 508-28.
  36. Stetler-Stevenson M, Mansoor A, Lim M, et al (1997). Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in reactive and neoplastic lymphoid cells. Blood, 89, 1708-15.
  37. Travaglino E, Benatti C, Malcovati L, et al (2008). Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. Eur J Haematol, 80, 216-26. https://doi.org/10.1111/j.1600-0609.2007.01012.x
  38. Vairaktaris E, Vassiliou S, Nkenke E, et al (2008). A metalloproteinase-9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma. Eur J Surg Oncol, 34, 450-5. https://doi.org/10.1016/j.ejso.2007.03.024
  39. Vundinti BR, Kerketta L, Jijina F, et al (2009). Cytogenetic study of myelodysplastic syndrome from India. Indian J Med Res, 130, 155-9.
  40. Westermarck J, Kahari VM (1999). Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J, 13, 781-92. https://doi.org/10.1096/fasebj.13.8.781
  41. Yang X, Liu Y, Yang Y, et al (2013). Update meta-analysis on MMP-7 -181A>G polymorphism and cancer risk: evidence from 25 studies. Gene, 521, 252-8. https://doi.org/10.1016/j.gene.2013.03.079
  42. Yu Q, Stamenkovic I (2000). Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev, 14, 163-76.
  43. Zhang C, Li C, Zhu M, et al (2013). Meta-analysis of MMP2, MMP3, and MMP9 promoter polymorphisms and head and neck cancer risk. PLoS One, 8, 62023. https://doi.org/10.1371/journal.pone.0062023

Cited by

  1. miRNA-301a induces apoptosis of chronic myelogenous leukemia cells by directly targeting TIMP2/ERK1/2 and AKT pathways vol.37, pp.2, 2016, https://doi.org/10.3892/or.2016.5330
  2. Expression and Activity of Matrix Metalloproteinases in Leukemia vol.41, pp.2, 2019, https://doi.org/10.1097/MPH.0000000000001386